Tricuspid Edge-to-Edge Repair has emerged as a promising alternative to surgical repair. Different studies have shown it is safe, reducing tricuspid regurgitation and effectively improving quality of life at 12 months.
Even though these are preliminary studies and have not shown long term benefits yet, we see promising present outcomes.
The bRIGHT study included 511 patients with tricuspid regurgitation undergoing edge-to-edge repair with TriClip. Mean age was 79, and 56% were women, 80% were in functional class III/IV, 23% had a pacemaker, AICD or resynchronization therapy, 40% had been hospitalized at least once in the past year and 40% presented kidney function deterioration.
In 90% of cases, TR was secondary. The most frequent was massive (61%), followed by torrential (27%) and, in lower number, severe.
Mean ejection fraction was 56%, with a coaptation gap of 6.49 mm, RV TAPSE 1.7, and right atrial volume 156 ml.
Read also: DIRECT TAVI: Is Predilation Important for Women?
At one-year follow-up, all-cause mortality was 15.1%, cardiac death 8.8%, hospitalization for cardiac failure 15.3%, new kidney function deterioration 5.5%, and need for pacemaker implantation 0.85%.
There was sustained reduction of tricuspid regurgitation to ≤ moderate in 81% of patients, with improved functional class and quality of life.
Conclusion
Tricuspid edge-to-edge repair TriClip resulted safe and effective at one year follow-up in patients with significant tricuspid regurgitation and advanced disease, according to real world data.
Original Title: Real-World 1-Year Results of Tricuspid Edge-to-Edge Repair. From the bRIGHT Study
Reference: Philipp Lurz, et al. J Am Coll Cardiol 2024;84:607–616.
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
